UroPredict relies on real world data from the UroCCR network to generate algorithms and implement them nationally for clinical research purposes.

A collaboration between the UroCCR Network / Cancer Committee of the French Association of Urology and SOPHiA GENETICS has enabled artificial intelligence algorithms to be developed and validated from the UroCCR database. The first released algorithms quantify the risk of upstaging from a cT1-2 kidney tumor on preoperative imaging to a pT3 tumor on pathological analysis, as well as the risk of recurrence after surgery of localized or locally advanced kidney cancer.


These predictive algorithms are freely available: - UroPredict 1 : Estimation of the upstaging risk of a cT1-2 stage tumour (Link publication)

- UroPredict 2 : Estimation of the recurrence risk after surgery for non-metastatic kidney cancer (Link publication) Link algorithm

UroPredict won the French government's "Data, AI & Healthcare Pathways" call for projects led by the Strategic Committee for the Healthcare Industries and Technologies Sector.